89Zr-trastuzumab-PET gauges treatment response in gastric cancer

04/24/2013 | HealthImaging.com

PET imaging with 89Zr-trastuzumab is effective in monitoring treatment response in animals with human epidermal growth factor receptor 2-positive stomach cancer being treated with afatinib, according to findings from a study published in The Journal of Nuclear Medicine. Researchers said 89Zr-trastuzumab-PET performed better than 18F-FDG-PET in determining drug uptake. There is a need for human studies to validate the efficacy of the method in monitoring treatment response, researchers added.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA